Filtered By:
Source: Circulation
Condition: Heart Failure
This page shows you your search results in order of relevance. This is page number 12.
Order by Relevance | Date
Total 195 results found since Jan 2013.
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure
Conclusions: In patients with HFpEF/HFmrEF, the presence of latent PVD uncovered by invasive hemodynamic exercise testing identifies patients who may worsen with atrial shunt therapy, whereas those without latent PVD may benefit.PMID:35354306 | DOI:10.1161/CIRCULATIONAHA.122.059486
Source: Circulation - March 31, 2022 Category: Cardiology Authors: Barry A Borlaug John Blair Martin W Bergmann Heiko Bugger Dan Burkhoff Leonhard Bruch David S Celermajer Brian Claggett John G F Cleland Donald E Cutlip Ira Dauber Jean-Christophe Eicher Qi Gao Thomas M Gorter Finn Gustafsson Chris Hayward Jan Van der Hey Source Type: research
Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial
CONCLUSION: Catheter ablation of atrial fibrillation was economically attractive compared with drug therapy in the CABANA Trial overall at present benchmarks for health care value in the United States on the basis of projected incremental QALYs but not LYs alone.PMID:35726631 | DOI:10.1161/CIRCULATIONAHA.122.058575
Source: Circulation - June 21, 2022 Category: Cardiology Authors: Derek S Chew Yanhong Li Patricia A Cowper Kevin J Anstrom Jonathan P Piccini Jeanne E Poole Melanie R Daniels Kristi H Monahan Linda Davidson-Ray Tristram D Bahnson Hussein R Al-Khalidi Kerry L Lee Douglas L Packer Daniel B Mark CABANA Investigators Source Type: research
Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage
CONCLUSIONS: Although in vascular smooth muscle, PDE3A mutations cause hypertension, they confer protection against hypertension-induced cardiac damage in hearts. Nonselective PDE3A inhibition is a final, short-term option in heart failure treatment to increase cardiac cAMP and improve contractility. Our data argue that mimicking the effect of PDE3A mutations in the heart rather than nonselective PDE3 inhibition is cardioprotective in the long term. Our findings could facilitate the search for new treatments to prevent hypertension-induced cardiac damage.PMID:36259389 | DOI:10.1161/CIRCULATIONAHA.122.060210
Source: Circulation - October 19, 2022 Category: Cardiology Authors: Maria Ercu Michael B M ücke Tamara Pallien Lajos Mark ó Anastasiia Sholokh Carolin Sch ächterle Atakan Aydin Alexa Kidd Stephan Walter Yasmin Esmati Brandon J McMurray Daniella F Lato Daniele Yumi Sunaga-Franze Philip H Dierks Barbara Isabel Montesinos Source Type: research
Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER
CONCLUSIONS: In DAPA-HF and DELIVER, the response to dapagliflozin was similar between men and women. Sex did not modify the treatment effect of dapagliflozin across the range of ejection fraction.PMID:36342789 | DOI:10.1161/CIRCULATIONAHA.122.062832
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Xiaowen Wang Muthiah Vaduganathan Brian L Claggett Sheila M Hegde Maria Pabon Ian J Kulac Orly Vardeny Eileen O'Meara Shelley Zieroth Tzvetana Katova Martina M McGrath Anne-Catherine Pouleur Pardeep S Jhund Akshay S Desai Silvio E Inzucchi Mikhail N Kosib Source Type: research
Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis
CONCLUSIONS: For older adults, taking more daily steps was associated with a progressively decreased risk of CVD. Monitoring and promoting steps per day is a simple metric for clinician-patient communication and population health to reduce the risk of CVD.PMID:36537288 | DOI:10.1161/CIRCULATIONAHA.122.061288
Source: Circulation - December 20, 2022 Category: Cardiology Authors: Amanda E Paluch Shivangi Bajpai Marcel Ballin David R Bassett Thomas W Buford Mercedes R Carnethon Ariel Chernofsky Erin E Dooley Ulf Ekelund Kelly R Evenson Deborah A Galuska Barbara J Jefferis Lingsong Kong William E Kraus Martin G Larson I-Min Lee Char Source Type: research
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial
CONCLUSIONS: The graded salutary relationship between efpeglenatide dose and cardiovascular outcomes suggests that titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to high doses may maximize their cardiovascular and renal benefits.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT03496298.PMID:36802715 | DOI:10.1161/CIRCULATIONAHA.122.063716
Source: Circulation - February 21, 2023 Category: Cardiology Authors: Hertzel C Gerstein Zhuoru Li Chinthanie Ramasundarahettige Seungjae Baek Kelley R H Branch Stefano Del Prato Carolyn S P Lam Renato D Lopes Richard Pratley Julio Rosenstock Naveed Sattar Source Type: research
